Related Experiment Video
Updated: Apr 22, 2026
Robotic Duodenum-preserving Total Pancreatic Head Resection for Intraductal Papillary Mucinous Neoplasms
Published on: April 17, 2026
Is it safe to follow side branch IPMNs?
Insights
Managing biliary-duct intraductal papillary mucinous neoplasms (Bd-IPMN) is difficult. Current treatments are unsatisfactory, leading to overtreatment; individualized care at expert centers is recommended, favoring older guidelines for safe lesion follow-up.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Hepatology
Background:
- Biliary-duct intraductal papillary mucinous neoplasms (Bd-IPMN) present diagnostic and management challenges.
- Current treatment strategies for presumed Bd-IPMN often result in overtreatment and surgical intervention.
- A critical appraisal of existing literature highlights the unsatisfactory outcomes associated with current management protocols.
Purpose of the Study:
- To critically evaluate the current management of Bd-IPMN.
- To provide recommendations for optimizing patient care and reducing unnecessary surgical interventions.
- To inform clinical decision-making regarding surveillance and treatment protocols for Bd-IPMN.
Main Methods:
- Comprehensive literature review and critical appraisal of published studies on Bd-IPMN management.
- Analysis of treatment outcomes and surgical overtreatment rates in patients with presumed Bd-IPMN.
- Comparative assessment of existing and proposed management guidelines.
Main Results:
- A high rate of surgical overtreatment is observed in patients presumed to have Bd-IPMN.
- Existing guidelines effectively identify lesions suitable for conservative management (surveillance).
- Newer guidelines allowing follow-up of larger lesions (>3 cm) require cautious application, especially in younger patients.
Conclusions:
- Individualized management tailored to patient-specific factors is crucial for presumed Bd-IPMN.
- Preference for older guidelines is suggested for most patients due to their proven efficacy in identifying safely followable lesions.
- Younger patients necessitate particularly close surveillance if managed under newer guidelines allowing for larger lesion follow-up.
Abstract:
Management of Bd-IPMN remains challenging. Critical appraisal of the published literature reveals that the actual treatment of what is presumed to be Bd-IPMN remains unsatisfactory, with a high rate of surgically overtreated patients. Until we accrue more precise knowledge of the natural history of Bd-IPMN, management of patients with this presumed diagnosis should be individually tailored and preferably carried out in centers with a high expertise. For now, the authors strongly think that the old guidelines should be followed in most patients because these have proven to correctly identify lesions that can be safely followed. Although the new guidelines allow for follow-up of lesions greater than 3 cm, and for the most part this is safe, they should be used cautiously in younger patients because very close surveillance would be required for their long remaining lifespan.
